Press release - Oslo, Norway, December 5th, 2022: Photocure ASA, The Bladder
Cancer Company, announces that new evidence was presented at the 22[nd] Annual
Society of Urologic Oncology (SUO) Meeting demonstrating that Blue Light
Cystoscopy (BLC[®]) decreases the risk and prolongs time to recurrence based on
Real World Evidence from the U.S. multi-institutional Blue Light Cystoscopy with
Cysview[®] Registry database.

This large, prospective, longitudinal, multisite registry collects data on
NMIBC* patients who have undergone transurethral resection of bladder tumor
(TURBT) using Blue Light as an adjunct to white light cystoscopy (WLC). The new
data represent an interim analysis of the study, which is projected to enroll
4,400 patients in total. In this study, all registry patients analyzed (n=2055)
received Blue Light. They were directly compared to a historical White-Light
(WL)-only control group (n=261) of similar age, stage, grade, and clinical
management (i.e., intravesical therapy).

Kaplan-Meier curves demonstrate recurrence-free survival (RFS) for BLC patients
compared to a WL-only arm with a mean follow up of 27.4 months for BLC and 53
months for the historical WL control arm. The overall risk of recurrence was
significantly lower following BLC compared to WLC alone (Hazard Ratio (HR) 0.33